CytoDyn has submitted its revised HIV clinical trial protocol to the FDA. The Company believes this submission will lead to the removal of the clinical hold currently in effect. In addition, the Company announced that its research partnership with Albert Einstein College of Medicine and Montefiore Medical Center is moving forward with a pre-clinical trial designed to study leronlimab in glioblastoma, a common and often untreatable form of primary brain cancer. Initial preparations have commenced for a trial to take place in 2024, one of potentially several pre-clinical trials to be conducted with Montefiore Medical Center.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CYDY:
- CytoDyn Releases Regulatory FD Disclosure Information
- CytoDyn Announces Executive Leadership Changes and Appointments
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
- CytoDyn appoints Jacob Lalezari as CEO, Michael Cohen as interim CFO
- CytoDyn Announces Webcast to Provide Company Update
